Dirk Witters
Directeur/Bestuurslid bij IMMUNOPRECISE ANTIBODIES LTD.
Vermogen: 2 328 $ op 30-04-2024
Profiel
Dirk Witters has held director positions at ImmunoPrecise Antibodies Ltd.
and BioStrand BV.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
19-01-2024 | 1 950 ( 0.01% ) | 2 328 $ | 30-04-2024 |
Actieve functies van Dirk Witters
Bedrijven | Functie | Begin |
---|---|---|
IMMUNOPRECISE ANTIBODIES LTD. | Directeur/Bestuurslid | 05-09-2023 |
BioStrand BV
BioStrand BV Miscellaneous Commercial ServicesCommercial Services Part of ImmunoPrecise Antibodies Ltd., BioStrand BV is a Belgian company that offers an AI-powered biotherapeutic SaaS platform to accelerate drug discovery. The company is based in Diepenbeek, Belgium. BioStrand's LensAI provides data solutions for simplified management, insights, integration, and collaboration. The platform helps researchers discover drug discovery insights faster and master big omics data challenges with multi-dimensional integration. The company was founded in 2019 by Dirk Van Hyfte and Ingrid Brands, with Ingrid Brands serving as the CEO since then. BioStrand was acquired by ImmunoPrecise Netherlands BV on April 14, 2022 for $35.10 million. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
IMMUNOPRECISE ANTIBODIES LTD. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
BioStrand BV
BioStrand BV Miscellaneous Commercial ServicesCommercial Services Part of ImmunoPrecise Antibodies Ltd., BioStrand BV is a Belgian company that offers an AI-powered biotherapeutic SaaS platform to accelerate drug discovery. The company is based in Diepenbeek, Belgium. BioStrand's LensAI provides data solutions for simplified management, insights, integration, and collaboration. The platform helps researchers discover drug discovery insights faster and master big omics data challenges with multi-dimensional integration. The company was founded in 2019 by Dirk Van Hyfte and Ingrid Brands, with Ingrid Brands serving as the CEO since then. BioStrand was acquired by ImmunoPrecise Netherlands BV on April 14, 2022 for $35.10 million. | Commercial Services |